Melbourne, June 2, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) provides the following update on the USA Patent Re-examination of the "Graham" patent 6,573,099.
In response to the formal Request for Oral Hearing filed in March 2010 and as announced in our market update on 9 March 2010, the Company has been notified that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office will hold an oral hearing re this matter on Wednesday 4 August 2010.
A combined team from Benitec and CSIRO, along with their attorneys, will attend this hearing.
A further update will be provided to the market following this hearing.
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
Mel Bridges Executive Director Benitec Limited Tel: +61-413-051-600 Email: firstname.lastname@example.org